I presume you are short and just trolling with ignorant commentary but we have the lowest PE of all major Bios on the ASX despite having amazing growth prospects with trof growth through
- organic as more patients exposed to drug not expected to peak for years
- increasing diagnosis of Retts increases universe of candidates for trof
- expanding markets to ROW (Canada is next)
- reformulation to reduce gastro issues
- development for FragileX
The lowest PE in major Bios on ASX discounts completely NNZ-2256 which has one successful Ph 2 under it's belt and three more to come in next 8 or 9 months. With 5x times the market size. That we own completely. Dubious Ph2 results? Said no one ever. But lol for the low content try to pump your bags
NEU Price at posting:
$18.65 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)